Oncology Expert Insights

Aaron Logan, MD, PhD, associate professor, clinical medicine in the Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine, member, UCSF Helen Diller Family Comprehensive Cancer Center; Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center

Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS

ByAaron Logan, MD, PhD,Bijal Shah, MD, MS

August 26th 2025

Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.

SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD

ByJason Luke, MD

August 25th 2025

Dr Luke discusses the rationale for evaluating IMA203 in cutaneous melanoma and what the PRAME trial findings may mean for the future of TCR therapy.

Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD

ByMasatoshi Kudo, MD, PhD

August 21st 2025

Masatoshi Kudo, MD, discusses the evolving treatment landscape in HCC and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens.

Ronan J. Kelly, MD, MBA, FASCO, director, Charles A. Sammons Cancer Center, chief science officer, Baylor University Medical Center, W.W. Caruth Jr. Endowed Chair of Immunology, Baylor University Medical Center, chief, Oncology, Baylor Scott & White Health System, founder and medical director, Texas Cancer Interception Institute, clinical professor, Texas A&M University College of Medicine, adjunct associate professor, oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, professor, Clinical Sciences Division, Translational Genomics Research Institute; Michelle Shiller, DO, AP/CP, MGP, molecular genetic pathologist, Baylor University Medical Center

Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP

ByRonan J. Kelly, MD, MBA, FASCO,Michelle Shiller, DO

August 19th 2025

Drs Kelly and Shiller discuss the importance of performing IHC testing for HER2 in NSCLC and recommendations for IHC testing implementation in practice.

Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD

By Neal S. Akhave, MD

August 14th 2025

Neal S. Akhave, MD, discusses the addition of toripalimab to the NCCN guidelines for nasopharyngeal carcinoma.

Advancing Treatment Strategies and Real-World Perspectives for mCRC and GI Neuroendocrine Neoplasms; With Rocío García-Carbonero, MD, PhD

ByRocio Garcia-Carbonero, MD, PhD

August 12th 2025

Rocío García-Carbonero, MD, PhD, discusses trends in colorectal cancer and other gastrointestinal malignancies, presented at the 2025 ESMO GI Cancers Congress.

The European Approval of Mirdametinib Expands the Treatment Paradigm for NF1-Associated Plexiform Neurofibromas: With Ignacio Blanco, MD, PhD

By Ignacio Blanco, MD, PhD

August 7th 2025

Ignacio Blanco, MD, PhD, discusses the EU marketing authorization of mirdametinib for patients with symptomatic, inoperable plexiform neurofibromas.

The Role of Combination Checkpoint Blockade Is Evolving in MSI-H mCRC: With Elena Élez, MD, PhD

ByElena Élez, MD, PhD

August 6th 2025

Elena Élez, MD, PhD, discusses the evolving role of immunotherapy for patients with microsatellite instability–high metastatic colorectal cancer.

Retrospective Data Highlight Improved Efficacy With Maintenance Therapy vs Treatment Breaks in mCRC: With Connie Lai, MD

ByConnie Lai, MD

July 31st 2025

Connie Lai, MD, discusses a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer.

Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center

Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD

ByJoshua K. Sabari, MD

July 24th 2025

Dr Sabari highlights key research investigating telisotuzumab vedotin in patients with c-Met–overexpressing non–small cell lung cancer.

Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC

ByBeth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Xavier Leleu, MD, PhD

July 21st 2025

Xavier Leleu, MD, PhD, and Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO, discuss key data from the phase 3 IRAKLIA study.

Arndt Vogel, MD, faculty member, University of Toronto Institute of Medical Science, scientist, Toronto General Hospital Research Institute, medical oncologist, UHN–Princess Margaret Cancer Centre

European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD

ByArndt Vogel, MD

July 17th 2025

Dr Vogel highlights the importance of the European Commission’s approval of zanidatamab for previously treated, metastatic HER2+ biliary tract cancer.

Justine Bruce, MD, faculty member, Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin; director, VA Medical Oncology Clinical Research Program, chair, Protocol Review and Monitoring Committee, University of Wisconsin Carbone Cancer Center

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

ByJustine Yang Bruce, MD

July 10th 2025

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Justin Moser, MD, associate clinical investigator, melanoma and cutaneous oncology specialist, phase 1 trialist, HonorHealth Research Institute; research associate professor, Arizona State University School of Medicine and Advanced Medical Engineering

IMA203 Emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD

ByJustin Moser, MD

June 30th 2025

Justin Moser, MD, discusses the ongoing phase 3 SUPRAME trial investigating IMA203 in previously treated, unresectable or metastatic cutaneous melanoma.

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine

T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD

ByMisako Nagasaka, MD, PhD

June 25th 2025

Dr Nagasaka discusses the evolving use of T-DXd for HER2-mutated NSCLC in light of the emergence of investigational agents in this setting.

Michael Dennis, MD, physician, Dana-Farber Cancer Institute; instructor, medicine, Harvard Medical School

Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD

ByMichael Dennis, MD

June 23rd 2025

Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.

Kate Gasparini, PharmD, BCOP, BCPPS, pediatric oncology clinical pharmacy specialist, Memorial Sloan Kettering Cancer Center

Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS

ByKate Gasparini, PharmD, BCOP, BCPPS

June 17th 2025

Kate Gasparini, PharmD, BCOP, BCPPS, discusses the oral formulation of imatinib for pediatric and adult patients with leukemias and other malignancies.

The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH

ByAlicia Morgans, MD, MPH, FASCO

June 16th 2025

Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.

T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD

ByPaolo Tarantino, MD

June 11th 2025

Paolo Tarantino, MD, discusses key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD

ByJonathan W. Goldman, MD

June 10th 2025

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET protein–overexpressing, nonsquamous, EGFR wild-type NSCLC.

Elizabeth Mittendorf, MD, PhD, MHCM, Robert and Karen Hale Distinguished Chair in Surgical Oncology, vice chair, research, Department of Surgery, Brigham and Women's Hospital; co-leader, Breast Program, director, Breast Immuno-Oncology Program, Dana-Farber Brigham Cancer Center; co-leader, Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute; professor, surgery, Harvard Medical School

Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM

ByElizabeth Mittendorf, MD, PhD, MHCM

June 9th 2025

Dr Mittendorf shares how ASCO plans to address the implications of federal research funding cuts and how structural reforms may bolster oncology progress.

Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM

ByElizabeth Mittendorf, MD, PhD, MHCM

June 2nd 2025

Dr Mittendorf discusses her priorities for advancing patient care and supporting up-and-coming oncology professionals during her 2026-2027 ASCO presidency.

Kanwarpal S. Kahlon, MD, associate clinical professor, medicine, UCLA School of Medicine

Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD

ByKanwarpal S. Kahlon, MD

May 22nd 2025

Dr Kahlon discusses the availability of the generic formulations of eltrombopag for patients with aplastic anemia and immune thrombocytopenia.

Michael J. Mauro, MD, attending physician, Memorial Sloan Kettering Cancer Center

Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD

ByMichael J. Mauro, MD

May 19th 2025

Dr Mauro discusses ways that the newest formulation of nilotinib for Ph-positive CML addresses treatment adherence issues by reducing the need for fasting.

Shubham Pant, MD, MBBS, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Professor Timothy Elliott, Kidani Professor of Immuno-oncology, Nuffield Department of Medicine, the University of Oxford

Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott

ByShubham Pant, MD, MBBS,Professor Timothy Elliott

May 15th 2025

Pant and Elliott discuss research seeking to extend the benefits of cancer vaccines as cancer management and prevention strategies.

Christopher L. Moertel, MD, professor, Pediatric Neuro-Oncology Fellowship Program director, Division of Pediatric Hematology/Oncology, faculty member, Department of Pediatrics, medical director, Pediatric Neuro-Oncology and Neurofibromatosis Programs, co-medical director, Katie Hageboeck Children’s Cancer Research Fund Clinic, clinical neuro-oncology leader, Brain Tumor Program, Kenneth and Betty Jayne Dahlberg Professor, University of Minnesota School of Medicine

MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD

ByChristopher L. Moertel, MD

May 12th 2025

Dr Moertel discusses the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib and selumetinib.

Anna C. Pavlick, BSN, MSc, DO, MBA, professor, medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine; founding director, Cutaneous Oncology Program, Weill Cornell Medicine and NewYork-Presbyterian

RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA

ByAnna C. Pavlick, DO

May 5th 2025

Dr Pavlick discusses the investigation of RP1 plus nivolumab in patients with advanced melanoma who have received prior immune checkpoint inhibition.

Nicole Lamanna, MD, hematologic oncologist, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian/Columbia University Irving Medical Center

Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD

ByNicole Lamanna, MD

April 28th 2025

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.

Daniel P. Petrylak, MD, professor, medicine (medical oncology) and urology, chief, Genitourinary Oncology, Yale School of Medicine and Smilow Cancer Hospital

Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

ByDaniel P. Petrylak, MD

April 24th 2025

Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Eric Christenson, MD, assistant professor, oncology, Johns Hopkins School of Medicine

Oncodetect MRD Test Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD

ByEric Christenson, MD

April 23rd 2025

Dr Christenson discusses the capabilities of the Oncodetect test, its clinical applications and pronostic value, and findings from the Alpha-CORRECT study.